Table 2.
The GRADE evidence quality for each outcome.
| Outcomes | No. of included trials | No. of patients | MD or RR (95% CI) | Heterogeneity | GRADE | |
|---|---|---|---|---|---|---|
| SEC150mg VS PLB | SEC150mg | PLB | ||||
| ASAS20 response | 4 | 388 | 389 | 1.71 (1.32, 2.22) | I 2 = 62%, P = 0.05 | Moderate |
| ASAS40 response | 4 | 388 | 389 | 2.16 (1.33, 3.53) | I 2 = 72%, P = 0.01 | Moderate |
| ASAS5/6 response | 4 | 388 | 389 | 2.87 (1.58, 5.24) | I 2 = 80%, P = 0.002 | Low |
| SF-36 PCS | 3 | 314 | 313 | 3.80 (2.52,5.08) | I 2 = 26%, P = 0.26 | High |
| ASQOL | 3 | 314 | 313 | −2.22 (-2.95, −1.49) | I 2 = 0%, P = 0.46 | High |
| AE | 4 | 388 | 388 | 1.07 (0.93, 1.24) | I 2 = 24%, P = 0.27 | High |
| SEC75mg VS PLB | SEC75mg | PLB | ||||
| ASAS20 response | 2 | 197 | 196 | 1.80 (1.28, 2.55) | I 2 = 39%, P = 0.20 | Moderate |
| ASAS40 response | 2 | 197 | 196 | 2.48 (1.62, 3.82) | I 2 = 0%, P = 0.92 | Moderate |
| ASAS5/6 response | 2 | 197 | 196 | 3.63 (2.37, 5.56) | I 2 = 0%, P = 0.68 | Low |
| SF-36 PCS | 2 | 197 | 196 | 3.91 (2.14, 5.68) | I 2 = 40%, P = 0.20 | Moderate |
| ASQOL | 2 | 197 | 196 | −2.33 (−3.26, −1.40) | I 2 = 0%, P = 0.53 | Moderate |
| AE | 2 | 197 | 196 | 1.06 (0.80, 1.39) | I 2 = 64%, P = 0.09 | Low |
| SEC75mg VS SEC150mg | SEC75mg | SEC150mg | ||||
| ASAS20 response | 2 | 197 | 197 | 0.67 (0.32, 1.42) | I 2 = 69%, P = 0.07 | Low |
| ASAS40 response | 2 | 197 | 197 | 0.77 (0.59, 1.01) | I 2 = 0%, P = 0.75 | Moderate |
| ASAS5/6 response | 2 | 197 | 197 | 0.89 (0.71, 1.11) | I 2 = 0%, P = 0.54 | Moderate |
| SF-36 PCS | 2 | 197 | 197 | −0.42 (−1.74, 0.89) | I 2 = 0%, P = 0.33 | Low |
| ASQOL | 2 | 197 | 197 | 0.24 (−0.68, 1.15) | I 2 = 0%, P = 0.47 | Moderate |
| AE | 2 | 197 | 197 | 0.94 (0.81, 1.08) | I 2 = 0%, P = 0.58 | Moderate |